Valeo Pharma Inc. (VPHIF)

0.0800 0.0000 (0.00%) As of 09:53AM EDT. Market open.

Valeo Pharma Inc.

16667 Hymus Boulevard
Kirkland, QC H9H 4R9
Canada
514-694-0150
https://www.valeopharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 100

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Steven Saviuk CA	Vice Chairman, President & CEO	183.05k	N/A	1959
Mr. Kyle Steiger	Senior VP & Chief Commercial Officer	228.45k	N/A	N/A
Mr. Pascal Tougas	Chief Financial Officer	N/A	N/A	N/A
Mr. Frederic Dumais	Director of Communications & Investor Relations	N/A	N/A	N/A
Mr. Guy-Paul Allard	VP of Legal Affairs & Corporate Secretary	N/A	N/A	N/A
Mr. Jean Francois Fournier	Head of Ophthalmology Business Unit	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic. In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products. The company was incorporated in 2003 and is based in Kirkland, Canada.

Corporate Governance

Valeo Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.